|Articles|October 1, 2002
New rules: FDA revises regulations to focus on health
Washington, DC-The FDA is revising its rules for safe drug manufacturing to direct more attention and resources to the aspects of manufacturing that pose the greatest risk to public health. It is the first time in 25 years the FDA is amending its rules.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
Alcon raises offer in amended deal to acquire STAAR Surgical
3
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
4
Neurotrophic keratitis outcomes improve with early, stage-based care
5










































.png)


